<DOC>
	<DOC>NCT02777567</DOC>
	<brief_summary>The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or after EGFR tyrosine kinase receptor (TKI) therapy.</brief_summary>
	<brief_title>KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>1. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutationpositive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative 1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug 2. Pregnancy and/or breast feeding 3. Current participation in any interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>